Cite
Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency.
MLA
Berger, Melvin, et al. “Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency.” Journal of Clinical Immunology, vol. 30, no. 2, Mar. 2010, pp. 321–29. EBSCOhost, https://doi.org/10.1007/s10875-009-9348-y.
APA
Berger, M., Pinciaro, P. J., Althaus, A., Ballow, M., Chouksey, A., Moy, J., Ochs, H., & Stein, M. (2010). Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency. Journal of Clinical Immunology, 30(2), 321–329. https://doi.org/10.1007/s10875-009-9348-y
Chicago
Berger, Melvin, Paul J. Pinciaro, Arthur Althaus, Mark Ballow, Akhilesh Chouksey, James Moy, Hans Ochs, and Mark Stein. 2010. “Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency.” Journal of Clinical Immunology 30 (2): 321–29. doi:10.1007/s10875-009-9348-y.